Press Release

Improving Wound Healing

Heel: Research study on a natural medication shows that it speeds up tissue repair and reduces lymphedema

Baden-Baden / Berlin (Germany) – Surgical treatments that remove or destroy parts of the lymphatic system are often followed by a painful secondary lymphedema. Lymphomyosot, a homeopathically prepared multi-target medication manufactured by Heel that is known for its positive effects on the lymphatic system is now being further examined. First study results have been presented on September 13, 2012, at the 38th Congress of Lymphology in Berlin (Germany). They show that the natural preparation significantly accelerates wound healing and reduces lymph congestion in the tissue.

The lymph, named after the Roman deity of fresh water, has astonishing capabilities. It is specialized in the transport of wastes. Next to the bloodstream, the lymphatic system with the lymph vessels as pathways is the most important transportation and communication system in the body – and it is crucially involved in the wound healing process and immune reaction.

"If the vessels of the lymphatic system get injured, however, the tissue fluid can no longer freely drain off. A congestion occurs that can lead to a lymphedema", says Dr. Bernd Seilheimer, Head of Global Research at Heel in Baden-Baden. "One of the most important targets is therefore to support the recovery of the tissue’s structures enabling a free lymphatic flow. In experimental models we have now been able to assert that our homeopathically manufactured multi-target preparation strongly accelerates wound closure and reduces the swelling significantly."

"We were surprised how clearly the experiments support the efficacy of this low-dose medication with its minimal side effects" says Jeremy Goldman, PhD. The Associate Professor and expert for lymphatic and blood vessel biology led the murine tests at the Department of Biomedical Engineering of the Michigan Technological University in Houghton, USA. "After the surgery, the swelling went down much faster with administration of the medication than in the saline control group. At the optimal dose, the wound closed more than twice as fast."
One of the main reasons for accelerated healing might lay in the targeting of underlying processes of lymphatic recovery and drainage, such as inflammation and tissue remodeling. The quantity of macrophages was reduced by almost 50 per cent as determined during the final examination in the Lymphomyosot group in comparison to the control group. The preparation seems to restore the lymphatic functionality after an injury and hence supports self-healing processes. Further studies will be conducted to provide more detailed information on the mode of action.

The study results were presented by Dr. rer. nat. Yvonne Burmeister at the 38th European Congress of Lymphology in Berlin. Under the auspices of the International Society of Lymphology and in cooperation with the German Society of Lymphologists the leading experts in the field of Lymphology come together annually to discuss the latest methods and treatment approaches, case studies and recent clinical findings. A leaflet on the study is available at Heel; a full publication in a peer-reviewed journal is in preparation.

499 words, 3264 characters (incl. blanks)

The study:
In experimental models of murine lymphedema the ability of a natural multi-target/multi-component medication was tested to reduce tissue swelling and support regeneration. The lymphedema was induced in balb/c mice by excising a 1 mm circular band of dermis containing the lymphatic capillary network 2 cm from the base of the tail. Underlying bone, muscle, tendons and major blood vessels were left intact. Mice were treated with the natural multi-target medication (5 µl or 25 µl, intraperitoneally injected) or saline as control on the day of surgery and every other day until day 30 (i. p. injection). It was demonstrated that the natural medication significantly reduced tissue swelling and increased the rate of surgical wound closure. These results brought on by low dose ingredients and with minimal side effects provide the opportunity to explore the potential therapeutic effects of the medication as a new systemic or local medication for wound therapy or skin repair to improve rate and quality of wound healing.

Heel is a pharmaceutical company that develops, manufactures and distributes medicines based on natural substances. As the global leader in homeopathic combination preparations, the company is also a pioneer in the field of scientific research in natural healthcare. In cooperation with academic institutions, Heel actively fosters the concept of integrative medicine and is building the bridge between homeopathy and conventional medicine to improve patient care and health.

Biologische Heilmittel Heel GmbH, with corporate headquarters located in Baden-Baden/Germany and a staff of 1,300, achieved an annual turnover of 196 million euros in 2011 – 70 percent of it outside of Germany. Heel medicines are available through subsidiaries and distribution partners in over 50 countries around the world. www.heel.com
At the 38th European Congress for Lymphology in Berlin, Dr. rer. nat. Yvonne Burmeister from Heel presented at the results of a new research study on the positive effects of a homeopathically prepared medication after injury of the lymphatic system. Photos: Heel / Bolesch. Photos in printable quality are available at: www.oha-communication.com/heel

Press contact:
Biologische Heilmittel Heel GmbH
Matthias Reinig
Head of Global Communication
Phone:  +49 7221 501-276
Fax:  +49 7221 501-480
E-mail:  matthias.reinig@heel.com
Internet:  www.heel.de / www.heel.com

Agency contact:
oha communication
Oliver Frederik Hahr
Director of Consulting and Public Relations
Phone:  +49 711 5088 6582-1
Fax:  +49 711 5088 6582-9
E-mail:  oliver.hahr@oha-communication.com
Internet:  www.oha-communication.com